2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161789
    PROTAC SARS-CoV-2 Mpro degrader-3 98%
    PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the main protease (Mpro) of human coronaviruses (HCoVs) (DC50=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC50 of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .
    PROTAC SARS-CoV-2 Mpro degrader-3
  • HY-161792
    N3-C5-O-C-Boc 2836521-02-7 98%
    N3-C5-O-C-Boc is a linker, which can be utilized for the synthesis of PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789).
    N3-C5-O-C-Boc
  • HY-161797
    Antibacterial agent 227 301304-67-6 98%
    Antibacterial agent 227 (Compd 29) is a SerRS (Seryl-tRNA synthetase) inhibitor. Antibacterial agent 227 has a significant inhibitory effect on the growth of planktonic and biofilm culture of Staphylococcus aureus 25923 with MIC (minimum inhibitory concentration) value of 32 µg/ml. Antibacterial agent 227 can be proposed as effective antiseptic toward multidrug-resistant biofilm-forming S. aureus isolates.
    Antibacterial agent 227
  • HY-161800
    Aminoacyl tRNA synthetase-IN-3 98%
    Aminoacyl tRNA synthetase-IN-3 (compound 36K3) is an inhibitor of lysine tRNA synthetase (PfLysRS) from Plasmodium falciparum (IC50=59.2 nM), which inhibits the activity of PfLysRS by occupying the ATP binding site and L-lysine binding site of PfLysRS. Aminoacyl tRNA synthetase-IN-3 can be used in the development of antimalarial drugs.
    Aminoacyl tRNA synthetase-IN-3
  • HY-161801
    MMV006833 701253-55-6 98%
    MMV006833 is an inhibitor for Plasmodium falciparum. MMV006833 targets the lipid-transfer protein PfSTART1 and inhibits the development of Plasmodium falciparum at the ring stage.
    MMV006833
  • HY-161802
    Antibacterial agent 228 98%
    Antibacterial agent 228 (Compound 8) inhibits the mycobacterial ribosome (IC50 for Mycobacterium smegmatis is 2.31 μM) and exhibits antibacterial activity against M. tuberculosis H37Rv (MIC=2 and 0.25 μg/mL for wildtype and Δ1258c mutant), M. abscessus ATCC 19977 (MIC=8 and 8 μg/mL for wildtype and Δ2780c mutant) and M. smegmatis (MIC=8 μg/mL).
    Antibacterial agent 228
  • HY-161803
    Anti-MRSA agent 12 2314380-76-0 98%
    Anti-MRSA agent 12 (Compound SM-5) is an antibiotic, which exhibits antibacterial activity against Staphylococcus aureus, S. epidermidis and Escherichia coli with MIC of 7.81, 7.81 and 62.5 μM. Anti-MRSA agent 12 inhibits the methicillin-resistant S. aureus (MRSA) through inhibition of biofilm formation.
    Anti-MRSA agent 12
  • HY-161805
    GNF-2-acid 714962-05-7 98%
    GNF-2-acid is a target protein ligand activity control that can be used for the synthesis of PROTACs (HY-161806) .
    GNF-2-acid
  • HY-161806
    ZXH-8-004 98%
    ZXH-8-004 (2-12-2-deg) is a potent DENV E PROTAC degrader with an DC50 value of 0.21 µM. ZXH-8-004 shows exhibit antiviral potencies (Blue: E3 ligase (HY-103596), Black: linker (HY-42149); Pink: DENV E ligand (HY-161807)).
    ZXH-8-004
  • HY-161807
    DENV ligand 1 1628758-48-4 98%
    DENV ligand 1 is a ligand for DENV E protein. DENV ligand 1 can be utilized for synthesis of PROTAC Degrader ZXH-8-004 (HY-161806).
    DENV ligand 1
  • HY-161808
    DENV ligand 2 98%
    DENV ligand 2 is the ligand for DENV E protein.DENV ligand 2 can be utilized for synthesis of PROTAC Degrader ZXH-8-004 (HY-161806). DENV ligand 2 is the active form of DENV ligand 1 (HY-161807).
    DENV ligand 2
  • HY-161813
    Antibacterial agent 229 3049500-54-8 98%
    Antibacterial agent 229 (compound 8a) is a potent antibacterial agent. Antibacterial agent 229 shows antibacterial and antifungal abilities. Antibacterial agent 229 disrupts the integrity of the bacterial membrane, intercalates into DNA. Antibacterial agent 229 inhibits topoisomerase IV with an IC50 value of 10.88 µM.
    Antibacterial agent 229
  • HY-161820
    IAV-IN-3 3049492-11-4 98%
    IAV-IN-3 (Compound (R,S)-16s) is an anti-influenza A virus (IAV) agent (EC50 = 0.134 μM) with weak cytotoxicity (CC50 = 15.35 μM for MDCK cells). IAV-IN-3 inhibits IAV polymerase with an IC50 of 0.045 μM.
    IAV-IN-3
  • HY-161822
    Antibacterial agent 230 3049368-26-2 98%
    Antibacterial agent 230 (compound 10) is an effective Antifungal agent. The MIC value of antibacterial agent 230 against fluconazole-resistant fungi is 2.0 ~ 16.0 μg/mL.
    Antibacterial agent 230
  • HY-161827
    Anti-MRSA agent 14 3050586-22-3 98%
    Anti-MRSA agent 14 (Compound C17) has antibacterial agent against MRSA and MRSA-infected skin murine model. Anti-MRSA agent 14 is more potential than Norfloxacin (HY-B0132) against MRSA. Anti-MRSA agent 14 disrupts cell membrane and restrains metabolism. Anti-MRSA agent 14 shows antibacterial effects against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA with MIC values of 1, 2, 2, 1 μM respectively.
    Anti-MRSA agent 14
  • HY-161837
    SARS-CoV-2 Mpro-IN-24 98%
    SARS-CoV-2 Mpro-IN-24 (Compound X77) is a inhibitor of SARS-CoV-2 Mpro (IC50=2.8 μM) and also a non-covalent inhibitor of SARS-CoV Mpro (IC50=3.4 μM).
    SARS-CoV-2 Mpro-IN-24
  • HY-161905
    ML471 2226227-77-4 98%
    ML471 is an oral active parasite tyrosyl-tRNA synthetase (PfTyrRS) inhibitor and can be used for study of malaria.
    ML471
  • HY-161935
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid 98%
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice.
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid
  • HY-161937
    Antibacterial agent 236 2364479-10-5 98%
    Antibacterial agent 236 (Compound 4l) is an orally active inhibitor for DNA gyrase and topoisomerase IV (IC50 is 3.2 and 300 nM in Staphylococcus aureus), and exhibits board-spectrum antibacterial activity. Antibacterial agent 236 exhibits good pharmacokinetic properties in mice.
    Antibacterial agent 236
  • HY-161955
    TMV-IN-11 2991481-09-3 98%
    TMV-IN-11 (compound syn-3g) is a potent TMV inhibitor with high inactivation capacity (IC50: 120.7 μg/mL). TMV-IN-11 can effectively inhibit the expression of TMV.
    TMV-IN-11
Cat. No. Product Name / Synonyms Application Reactivity